PointState Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

PointState Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,000	Closed	-$2.69M	–	154
2021 Q4	$2.69M	Sell	25,000 -20,000	-44%	-$2.18M	0.04%	102
2021 Q3	$4.93M	Sell	45,000 -10,000	-18%	-$1.04M	0.08%	104
2021 Q2	$5.15M	Buy	+55,000	New	+$5.06M	0.09%	93
2021 Q1	–	Sell	-26,250	Closed	-$1.92M	–	172
2020 Q4	$1.92M	Buy	+26,250	New	+$1.95M	0.04%	112
2016 Q4	–	Sell	-100,000	Closed	-$1.81M	–	186
2016 Q3	$1.81M	Buy	+100,000	New	+$1.95M	0.02%	132
2015 Q2	–	Sell	-250,000	Closed	-$6.49M	–	186
2015 Q1	$6.49M	Buy	+250,000	New	+$4.58M	0.09%	91

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PointState Capital's HZNP Position: Q1 2022 in Review

PointState Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 25,000 shares — an estimated $2.69M sold.

PointState Capital first reported a position in HZNP in Q1 2015 and held it in 6 quarters. The position peaked at $6.49M in Q1 2015. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

PointState Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
PointState Capital sold 25,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $2.69M.
PointState Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 6 quarters.
PointState Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.49M in Q1 2015.
620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.